FDA Beats Ranbaxy Suit Despite 'Serious' Approval Errors
The U.S. Food and Drug Administration acted within its authority when it stripped Ranbaxy Laboratories Ltd. of tentative approvals for two generics, but the agency also made "serious errors" by granting...To view the full article, register now.
Already a subscriber? Click here to view full article